AbbVie (NYSE:ABBV) Trading 0.8% Higher - Here's Why

AbbVie Inc. (NYSE:ABBV - Get Free Report)'s share price was up 0.8% during mid-day trading on Monday . The stock traded as high as $178.13 and last traded at $177.57. Approximately 765,093 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 5,508,982 shares. The stock had previously closed at $176.19.

Wall Street Analyst Weigh In

ABBV has been the subject of several research reports. Morgan Stanley reduced their price objective on AbbVie from $231.00 to $224.00 and set an "overweight" rating for the company in a research note on Tuesday, November 12th. BMO Capital Markets decreased their price target on AbbVie from $228.00 to $208.00 and set an "outperform" rating for the company in a research report on Tuesday, November 12th. Wells Fargo & Company boosted their price objective on AbbVie to $195.00 and gave the stock a "buy" rating in a report on Tuesday, November 19th. Leerink Partners upgraded shares of AbbVie from a "market perform" rating to an "outperform" rating and set a $206.00 target price for the company in a report on Friday, November 22nd. Finally, Citigroup cut their price target on shares of AbbVie from $226.00 to $215.00 and set a "buy" rating on the stock in a report on Tuesday, November 12th. Five research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, AbbVie currently has an average rating of "Moderate Buy" and a consensus price target of $202.38.

AbbVie Trading Up 0.6 %

The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65. The company has a market capitalization of $313.23 billion, a P/E ratio of 61.66, a P/E/G ratio of 2.01 and a beta of 0.58. The company has a 50-day simple moving average of $186.76 and a 200 day simple moving average of $182.54.

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Wednesday, October 30th. The company reported $3.00 EPS for the quarter, beating the consensus estimate of $2.92 by $0.08. The firm had revenue of $14.46 billion during the quarter, compared to analysts' expectations of $14.28 billion. AbbVie had a net margin of 9.22% and a return on equity of 244.01%. The business's quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the company earned $2.95 EPS. Sell-side analysts expect that AbbVie Inc. will post 10.95 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be given a $1.64 dividend. This is a boost from AbbVie's previous quarterly dividend of $1.55. This represents a $6.56 annualized dividend and a yield of 3.70%. The ex-dividend date of this dividend is Wednesday, January 15th. AbbVie's dividend payout ratio (DPR) is 215.28%.

Institutional Trading of AbbVie

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Fairway Wealth LLC bought a new position in shares of AbbVie during the 2nd quarter worth approximately $26,000. Ridgewood Investments LLC bought a new stake in shares of AbbVie in the 2nd quarter worth about $27,000. Groupama Asset Managment increased its position in shares of AbbVie by 40.3% during the 3rd quarter. Groupama Asset Managment now owns 135,749 shares of the company's stock worth $27,000 after purchasing an additional 38,974 shares in the last quarter. RPg Family Wealth Advisory LLC acquired a new position in AbbVie in the third quarter valued at about $28,000. Finally, Quest Partners LLC grew its stake in AbbVie by 4,140.0% during the second quarter. Quest Partners LLC now owns 212 shares of the company's stock worth $36,000 after buying an additional 207 shares during the last quarter. Institutional investors own 70.23% of the company's stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.